@article{3a6b427bde6b48ee80f0b0122719668f,
title = "Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenstr{\"o}m's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study.",
author = "Christian Buske and Alessandra Tedeschi and Judith Trotman and Ram{\'o}n Garc{\'i}a-Sanz and David MacDonald and Veronique Leblond and Beatrice Mahe and Charles Herbaux and Matous, \{Jeffrey V\} and Tam, \{Constantine S\} and Heffner, \{Leonard T\} and Marzia Varettoni and Palomba, \{M Lia\} and Chaim Shustik and Efstathios Kastritis and Treon, \{Steven P\} and Jerry Ping and Bernhard Hauns and Israel Arango-Hisijara and Dimopoulos, \{Meletios A\}",
note = "PURPOSE The double-blind, randomized, placebo-controlled phase III iNNOVATE study showed sustained efficacy of ibrutinib-rituximab in Waldenstr{\"o}m's macroglobulinemia (WM). Here, we present the final analysis from iNNOVATE. METHODS Patients had confirmed symptomatic WM, either previously untreated or previously treated; patients with prior rituximab had at least a minor response to their last rituximab-based regimen.",
year = "2021",
month = oct,
day = "4",
doi = "10.1200/JCO.21.00838",
language = "American English",
journal = "Journal of Clinical Oncology",
}